Gilead lowers US state programme price for HIV combo Stribild after public criticism
22:50 EDT 9 Sep 2012 | SCRIP
The ADAP Crisis Task Force (ACTF) has negotiated a price reduction on behalf of US state AIDS Drug Assistance Programs (ADAPs) for Gilead Sciences' new four-in-one HIV drug Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil....
Original Article: Gilead lowers US state programme price for HIV combo Stribild after public criticism
More From BioPortfolio on "Gilead lowers US state programme price for HIV combo Stribild after public criticism"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
